DMD Noab BioDiscoveries - Shaping Drug Discovery

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
QUICK SEARCH:   [advanced]


     

Drug Metabolism and Disposition Fast Forward
First published on August 15, 2005; DOI: 10.1124/dmd.105.005454

This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.105.005454v1
33/11/1748    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Author home page(s):
Wolfgang Volkel
Nataly Bittner
Wolfgang Dekant
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Volkel, W.
Right arrow Articles by Dekant, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Volkel, W.
Right arrow Articles by Dekant, W.


Received for publication May 12, 2005.
Revised July 14, 2005.
Accepted for publication August 15, 2005.

Quantitation of bisphenol A and bisphenol A glucuronide in biological samples by HLPC-MS/MS

Wolfgang Volkel 1, Nataly Bittner 1, Wolfgang Dekant 1*

1 Department of Toxicology, University of Wuerzburg

* Address correspondence to: E-mail: dekant{at}toxi.uni-wuerzburg.de

Abstract

Bisphenol A (BPA) is a weak estrogen. Pharmacokinetic studies of BPA have demonstrated a rapid and extensive metabolism of BPA to the non-estrogenic BPA-monoglucuronide (BPA-gluc). Some investigators have reported that BPA was found at parts per billion concentrations in the tissues or urine of humans without known exposure to BPA. This work developed a rapid and sensitive method for the determination of BPA and BPA-gluc in plasma and urine based on LC-MS/MS. The LC-ESI-MS/MS method for quantitation of BPA and BPA-gluc uses stable isotope labelled internal standards. A linear ion trap mass spectrometer permits identification and quantitation of BPA-gluc and BPA without sample workup. Development of separation conditions reduced the BPA-background in solvent samples to below 2.5 pmol/mL for BPA. Limit of quantitation (LOQ) for BPA in control urine was 15 pmol/mL, LOQ for BPA-gluc was 65 pmol/mL. Application of the method to urine samples from human subjects (n = 6) after administration of 25 µg BPA/person (estimated maximum human daily intake) permitted the determination of excretion kinetics for BPA-gluc; BPA was below the LOD in all except two of the samples. In urine or blood samples of human subjects (n = 19) without intentional exposure to BPA, BPA-concentrations were always below the limit of detection ({approx} 2.5 pmol/mL) with or without prior glucuronidase treatment. The results show that care is required for analysis of BPA and its major metabolite BPA-gluc. The LOD obtained and the absence of detectable levels of BPA in samples from individuals suggests that general exposure of humans to BPA is much lower than worst-case exposure scenario developed.


Key words: analytical chemistry, analytical pharmacology/toxicology, chemical toxicology, endocrine regulation, human pharmacokinetics, mass spectrometry, phase II drug metabolism, toxicology


This article has been cited by other articles:


Home page
 Toxicol SciHome page
U. M. D. Schauer, W. Volkel, and W. Dekant
Toxicokinetics of Tetrabromobisphenol A in Humans and Rats after Oral Administration
Toxicol. Sci., May 1, 2006; 91(1): 49 - 58.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics.